Autopsy report · NCT05689021

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

“Sponsor decided to close due to slow accrual and lack of efficacy”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 2 months before it started.
• Ran for about 2 years 4 months before it stopped.
• 8 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Mayo Clinic

Sponsor type

University, hospital or other

Conditions

Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8

Interventions

Abiraterone Acetate/Niraparib; Biospecimen Collection; Bone Scan; Computed Tomography; Magnetic Resonance Imaging; Prednisone

Participants

8

Sites

3

Countries

United States

Trials that died the same way

• ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma
  “Sponsor has decided to close study.” (79% match in meaning)
• A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
  “Sponsor Decision to close study” (77% match in meaning)
• Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy
  “Sponsor decision to close study early; not due to safety concerns” (76% match in meaning)
• Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
  “Closed by sponsor” (73% match in meaning)
• Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts
  “Sponsor decision due to low accrual” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.